



INVESTOR IN PEOPLE

PCT/GB00/02879

10/031786

## PRIORITY DOCUMENT

SUBMITTED OR TRANSMITTED IN  
COMPLIANCE WITH RULE 17.1(a) OR (b)

The Patent Office  
Concept House  
Cardiff Road  
Newport  
South Wales

#2

NP10 8QQ

REC'D 18 AUG 2000

WIPO

PCT

I, the undersigned, being an officer duly authorised in accordance with Section 74(1) and (4) of the Deregulation & Contracting Out Act 1994, to sign and issue certificates on behalf of the Comptroller-General, hereby certify that annexed hereto is a true copy of the documents as originally filed in connection with the patent application identified therein.


GB 00/02879

4

In accordance with the Patents (Companies Re-registration) Rules 1982, if a company named in this certificate and any accompanying documents has re-registered under the Companies Act 1980 with the same name as that with which it was registered immediately before re-registration save for the substitution as, or inclusion as, the last part of the name of the words "public limited company" or their equivalents in Welsh, references to the name of the company in this certificate and any accompanying documents shall be treated as references to the name with which it is so re-registered.

In accordance with the rules, the words "public limited company" may be replaced by p.l.c., plc, P.L.C. or PLC.

Re-registration under the Companies Act does not constitute a new legal entity but merely subjects the company to certain additional company law rules.



Signed

*P. Mahoney*

Dated

03 AUG 2000

.....

# Patents Form 1/77

Patent Act 1977  
(Rule 1)

The  
**Patent  
Office**

Patent Office  
Cardiff Road  
Newport  
Gwent NP9 1RH

The Patent Office

Cardiff Road  
Newport  
Gwent NP9 1RH

## Request for grant of a patent

(See the notes on the back of this form. You can also get an explanatory leaflet from the Patent Office to help you fill in this form)

1. Your reference	P76036 GCW		
2. Patent application number (The Patent Office will fill in this part)	9917531.7		26 JUL 1999
3. Full name, address and postcode of the or of each applicant (underline all surnames)	ARROW THERAPEUTICS LIMITED Woodmansterne Road Carshalton Surrey SM5 4DS United Kingdom  Patents ADP number (if you know it)  If the applicant is a corporate body, give the country/state of its incorporation		
4. Title of the invention	TRANSPONON MEDIATED DIFFERENTIAL HYBRIDISATION		
5. Name of your agent (if you have one)	J A KEMP & CO		
"Address for service" in the United Kingdom to which all correspondence should be sent (including the postcode)	14 SOUTH SQUARE GRAY'S INN LONDON WC1R 5LX  Patents ADP number (if you know it)		
6. If you are declaring priority from one or more earlier patent applications, give the country and the date of filing of the or of each of these earlier applications and (if you know it) the or each application number	Country	Priority application number (if you know it)	Date of filing (day / month / year)
7. If this application is divided or otherwise derived from an earlier UK application, give the number and the filing date of the earlier application	Number of earlier application		Date of filing (day / month / year)
8. Is a statement of inventorship and of right to grant of a patent required in support of this request? (Answer "Yes" if: a) any applicant named in part 3 is not an inventor, or b) there is an inventor who is not named as an applicant, or c) any named applicant is a corporate body: See note (d))	YES		



## Patents Form 1/77

9. Enter the number of sheets for any of the following items you are filing with this form. Do not count copies of the same document

Continuation sheets of this form

Description	29
Claim(s)	5
Abstract	1
Drawing(s)	5 + 5



10. If you are also filing any of the following, state how many against each item.

Priority documents


Translations of priority documents

Statement of inventorship and right to grant of a patent (*Patents Form 7/77*)

Request for preliminary examination and search (*Patents Form 9/77*)

Request for substantive examination (*Patents Form 10/77*)

Any other documents  
(please specify)

- |     |  |
|-----|--|
| 11. | I/We request the grant of a patent on the basis of this application  |
|     | Signature  Date 26 July 1999 |
| 12. | Name and daytime telephone number of person to contact in the United Kingdom                                     |
|     | G.C. WOODS<br>0171 405 3292  |

### Warning

After an application for a patent has been filed, the Comptroller of the Patent Office will consider whether publication or communication of the invention should be prohibited or restricted under Section 22 of the Patents Act 1977. You will be informed if it is necessary to prohibit or restrict your invention in this way. Furthermore, if you live in the United Kingdom, Section 23 of the Patents Act 1977 stops you from applying for a patent abroad without first getting written permission from the Patent Office unless an application has been filed at least 6 weeks beforehand in the United Kingdom for a patent for the same invention and either no direction prohibiting publication or communication has been given, or any such direction has been revoked.

### Notes

- If you need help to fill in this form or you have any questions, please contact the Patent Office on 0645 500505.
- Write your answers in capital letters using black ink or you may type them.
- If there is not enough space for all the relevant details on any part of this form, please continue of a separate sheet of paper and write "see continuation sheet" in the relevant part(s). Any continuation sheet should be attached to this form.
- If you have answered "Yes" Patents Form 7/77 will need to be filed.
- Once you have filled in the form you must remember to sign and date it.
- For details of the fee and ways to pay please contact the Patent Office.

**TRANSPOSON MEDIATED DIFFERENTIAL**  
**HYBRIDISATION**

**Field of The Invention**

5           The invention relates to methods for the isolation of genes which are essential  
for the survival of an organism and to antibacterials, fungicides, antiparasitics,  
pesticides and herbicides.

**Background to The Invention**

10           Various strategies to generate and characterize mutations in a number or  
organisms have been described that rely on transposon mutagenesis. Such  
approaches depend on survival of the particular organism following mutagenesis and  
thus only detect mutants in which transposons have inserted into non-essential genes.  
Mutagenesis protocols have been developed for some conditional states, comparing  
15   *in vitro* growth with *in vivo* survival, and the Signature Tagged Mutagenesis (STM)  
approach has been particularly successful in identifying mutants important in  
pathogenicity. However, these conditional methods cannot detect mutants in genes  
that are essential for bacterial survival and which when mutated result in a lethal  
phenotype.

20           However, essential genes and in particular the proteins which they encode  
may be good substrates for use in screens for antibacterials, antiparasitics, fungicides,  
pesticides and herbicides. The increase in prevalence of antibiotic-resistant bacteria,  
for example, has renewed interest in the search for new targets for antibacterial  
agents. Essential genes and their protein products potentially represent such targets.

25           Additionally, there is an interest in the identification of conditional essential  
genes, that is genes which are essential for the survival of an organism in a particular  
environment. In the case of pathogenic bacteria, for example, these are genes which  
may be required for survival in the host. Such genes and the proteins which they  
encode may be good targets for use in screens for antibacterials. Bacteria which  
30   carry mutations in such genes may be useful in attenuated live vaccines.

### **Summary of The Invention**

We have devised a general method to identify all the essential genes in a bacterial genome, using a transposon mutagenesis technique. We have called the technique Transposon Mediated Differential Hybridisation (TMDH). Essential genes  
5 are those genes which, when missing (eg. because of a chromosomal deletion) or  
~~mutated to render them non-functional, result in a lethal phenotype. That is, genes~~  
without which a bacterium cannot survive.

The technique can also be used for the identification of conditional essential genes. Conditional essential genes are those genes which are not absolutely essential  
10 for bacterial survival, but which are essential for survival under various conditional restraints. Examples of particular conditional restraints include survival at elevated temperatures and survival of a pathogen within its host.

According to the present invention there is thus provided a method for identifying an essential gene of an organism, comprising:  
15 (i) providing a library of transposon mutants of the said organism;  
(ii) isolating polynucleotide sequences from the library which flank inserted transposons;  
(iii) hybridising the said polynucleotide sequences with a polynucleotide library from the said organism; and  
20 (iv) identifying a polynucleotide in the said polynucleotide library to which the said polynucleotide sequences do not hybridise, thereby to determine an essential gene of the organism.

The invention also provides:

- a method for identifying a conditional essential gene of an organism  
25 comprising:
  - (i) providing a first sample of a library of transposon mutants of the said organism (input library);
  - (ii) providing a second sample of the library and subjecting that sample to a conditional restraint;
  - 30 (iii) collecting the mutants that survive the conditional restraint in step (ii) to give a new library (output library);

- (iv) carrying out a method for identifying an essential gene of an organism on the input library from step (i) and on the output library from step (iii), thereby to determine a conditional essential gene of the organism;
- 5        –        use of an essential or conditional essential gene identified by a method of the invention or a polypeptide encoded by a said gene, in a method for identifying an inhibitor of transcription and/or translation of that gene and/or activity of a polypeptide encoded by that gene;
- 10       –        a method for identifying:
  - (i)        an inhibitor of transcription and/or translation of an essential or conditional essential gene identified by a method of the invention; and/or
  - (ii)       an inhibitor of activity of a polypeptide encoded by a said gene, which method comprises determining whether a test substance can inhibit
  - 15       transcription and/or translation of a said gene and/or activity of a polypeptide encoded by a said gene;
- 20       –        an inhibitor identified by a method for identifying an inhibitor of transcription and/or translation of an essential or conditional essential gene identified by a method of the invention and/or activity of a polypeptide encoded by that gene;
- 25       –        an inhibitor of transcription and/or translation of an essential or conditional essential gene and/or activity of a polypeptide encoded by that gene;
- 30       –        an inhibitor of the invention, wherein the essential or conditional essential gene is a bacterial, fungal or eukaryotic parasite essential or conditional essential gene;
- an inhibitor of the invention for use in a method of treatment of the human or animal body by therapy;
- use of an inhibitor of the invention for the manufacture of a medicament for use in the treatment of a bacterial, fungal or eukaryotic parasite infection.
- a pharmaceutical composition comprising an inhibitor of the invention and a pharmaceutically acceptable carrier or diluent;

- a method of treating a host suffering from a bacterial, fungal or eukaryotic parasite infection, which comprises administering to the host a therapeutically effective amount of an inhibitor of the invention;
- an inhibitor of the invention, wherein the essential or conditional essential gene is a bacterial, fungal or pest essential or conditional essential gene;
- ~~– use of an inhibitor of the invention as a plant bacteriocide, fungicide or pesticide;~~
- an inhibitor of the invention, wherein the essential or conditional essential gene is a plant conditional or essential gene;
- use of an inhibitor according of the invention as a herbicide;
- a method for identifying a conditional essential gene of an organism, wherein the organism is a bacterium and the conditional restraint is growth of that bacterium in its host;
- a bacterium attenuated by a non-reverting mutation in one or more genes identified by a method for identifying a conditional essential gene of an organism;
- a vaccine comprising a bacterium of the invention and a pharmaceutically acceptable carrier or diluent;
- a bacterium of the invention for use in a method of vaccinating a human or animal;
- use of a bacterium of the invention for the manufacture of a medicament for vaccinating a human or animal; and
- a method of raising an immune response in a mammalian host, which comprises administering to the host a bacterium of the invention.

#### **Brief Description of The Figures**

Figure 1 shows a diagrammatic representation of one potential scheme for carrying out Transposon Mediated Differential Hybridisation (TMDH).

Genomic DNA isolated from a library of bacteria previously subjected to mutagenesis with a transposon is digested with left- and right-arm transposon-specific (TS) and gene-specific (GS) restriction endonucleases. For the



transposon *TnphoA*, the left-arm restriction endonuclease pair may be *DraI/HaeIII* and the right arm pair may be *HpaI/HaeIII*.

Restriction fragments in the 200 to 600 base pair (bp) range are purified following gel electrophoresis and vectorette units with compatible ends are ligated to the purified fragments. The resulting separate fragment panels (ie. the left-arm and right-arm panels) may be further purified at this stage.

Polymerase chain reaction (PCR) is carried out on the left-arm and right-arm fragment panels using primer pairs comprising an oligonucleotide specific for a transposon sequence and a second oligonucleotide specific for a vectorette sequence. The two panels of PCR fragments thus generated constitute the left- and right-arm consensus probes, representing sequences from the genes that have been disrupted by transposon insertion. The panels of PCR fragments can be radioactively labelled and used in hybridization experiments.

Figure 2 shows that the left- and right-arm consensus probes can generate different signals. TMDH uses probes derived from left- and right-arm regions flanking the sites of transposon insertions. Figure 2 outlines a theoretical situation where an essential gene (gene b) is flanked by two non-essential genes. In diagrams A and B, transposons have inserted into regions of the non-essential gene a. Both left- and right-arm consensus probes comprise mainly sequences from the non-essential gene a. However, in C, where the transposon has inserted towards the end of a, part of the resulting consensus right-arm probe may hybridise with the essential gene b. A similar situation can also occur for transposon insertion within the non-essential gene c, where a component of the left-arm consensus probe may hybridize with the essential gene b. The differential analysis of the hybridisation signals produced from the two probes allows an interpretation to be made in terms of whether or not the gene is essential.

Figure 3 shows agarose gel electrophoresis of  $\lambda$  *TnphoA* transposon library left- and right-arm PCR products. Lanes 1 and 6, 100bp ladder; lane 2, left-arm PCR products; lane 4, right-arm PCR products. Lanes 3 and 5, PCR of DNA from

the host strain (*E. coli* XAC) with left-arm and right-arm PCR primers, respectively. Note the absence of any PCR product from the control lanes 3 and 5.

Figure 4 shows hybridisation of consensus probes to a gridded array of *E. coli* open reading frames. In (a) hybridisation is shown of the <sup>33</sup>P-labelled left-arm probe to the Panorama Gene Array (Sigma-Genosys Ltd). The three fields contain 4290 PCR-amplified open reading frames representing all *E. coli* protein coding genes. A positive hybridisation signal corresponds to a gene that has been disrupted by transposon insertion, thereby identifying a non-essential gene.

In (b) hybridisation is shown of the <sup>33</sup>P-labelled right-arm probe with the Panorama Gene Arrays (Sigma-Genosys Ltd). The three fields contain 4290 PCR-amplified open reading frames representing all *E. coli* protein coding genes. A positive hybridisation signal corresponds to a gene that has been disrupted by transposon insertion, thereby identifying a non-essential gene.

### **Detailed Description of The Invention**

The invention provides a method for identifying essential genes of an organism. Typically, the method requires the construction of a library of transposon mutants of a particular organism.

The library of transposon mutants can be used to generate a "consensus probe" which comprises a complex pool of polynucleotide sequences from the mutants in the library. The consensus probe comprises polynucleotide sequences which flank the transposon insertion sites and thus comprises sequences from genes that are non-essential. The particular method used to generate the consensus probe may allow the isolation of sequences from one or both regions flanking the transposons.

The consensus probe is hybridized to polynucleotides from the organism used to generate the transposon-tagged mutants. Polynucleotides that do not hybridize to the consensus probe may correspond to genes that are essential for the survival of the organism in question.

### Construction of a library of transposon mutants

Typically, a library of transposon mutants is generated. Transposons, sometimes called transposable elements, are mobile polynucleotides. The term transposon is well known to those skilled in the art and includes classes of transposons that can be distinguished on the basis of sequence organisation, for example short inverted repeats at each end; directly repeated long terminal repeats (LTRs) at the ends; and polyA at 3' ends of RNA transcripts with 5' ends often truncated. Some types of virus also integrate into the host genome, for example retroviruses, and may therefore be used to generate libraries of insertion mutants. However, transposons are typically preferred to viruses because issues of safety related to pathogenicity may be avoided.

Any suitable transposon may be used for the generation of transposon libraries.

Suitable bacterial transposons include Tn3,  $\gamma\delta$ , Tn10, Tn5, TnphoA, Tn903, Tn917, Bacteriophage Mu and related viruses. Any of the above mentioned transposons may be used in a method of the invention. Preferred transposons are those which carry antibiotic resistance genes (which may be useful in identifying mutants which carry a transposon) including Tn5, Tn10 and TnphoA. For example, Tn10 carries a tetracycline resistance gene between its IS elements and Tn5 carries genes encoding polypeptides conferring resistance to kanamycin, streptomycin and bleomycin. It is of course possible to generate new transposons by inserting different combinations of antibiotic resistance genes between its IS elements or by altering the polynucleotide sequence of the transposon, for example by making a redundant base substitution in the coding region of an antibiotic resistance gene. It will be apparent that such transposons are included within the scope of the invention.

Suitable fungal transposable elements include the *Ty1* element of *Saccharomyces cerevisiae*, the filamentous fungi elements (the filamentous fungi include agriculturally important plant pathogens such as *Erysiphe graminis*, *Magnaporthe grisea*) such as *Fot1/Pogo*-like and *Tc1/Mariner*-like elements (see Kempen and Kuck, 1998, Bioessays 20, 652-659 for a review of such elements).

Suitable plant elements include *Ac/Ds*, *Tam3* and other *Tam* elements, *cin4*

and *spm*.

Suitable animal elements include *P* and *hobo* which may be used in *Drosophila* and *Tc1* which can be used in *Caenorhabditis elegans*.

Libraries of transposon mutants may be generated according to any method  
5 known to those skilled in the art. For example, libraries of bacterial transposon  
~~mutants can be constructed using either plasmid or bacteriophage vectors containing~~  
the transposon and a selectable marker. Bacteriophage  $\lambda$  eg.  $\lambda$ Tn $\phi$ hoA can be used to  
infect a suitable recipient bacterial strain, for example *E. coli* XAC. This *E. coli*  
strain has a suppressor mutation which prevents the bacteriophage from replicating  
10 and subsequently lysing and also contains an antibiotic resistance gene to allow  
selection of colonies containing transposed chromosomal DNA. The vector contains  
mutation(s) preventing integration of the  $\lambda$  chromosome into the host (bacterial)  
chromosome and thus the growth of false positive colonies without a mutated *E. coli*  
gene is prevented. Cultures of the recipient strain are grown in enriched medium (eg.  
15 Luria Broth) and cells in mid log phase of growth are infected with the  $\lambda$  transposon  
vector for 1 hour at 37°C. Aliquots of the infected cells are plated out on L-agar  
supplemented with the appropriate selective antibiotic and grown overnight at 37°C.  
These colonies constitute a transposon library and can be further analysed by the  
TMDH procedure described in this application.

20 Growth of such libraries results in the generation of thousands of mutants and  
these result from mutations that are all, of necessity, in genes that when mutated do  
not result in the death of the cell ie. the non-essential genes. Typically, such a library  
will comprise at least one transposon insertion in at least 80%, preferably at least  
90%, more preferably, at least 95% and most preferably at least 99% of non-essential  
25 genes.

Some regions of a particular genome may be inaccessible to insertion by a  
particular transposon, for example because of a particular secondary or tertiary  
structure which is inaccessible to a particular transposon. Thus it may be  
advantageous to combine two transposon libraries, thereby increasing the probability  
30 of obtaining transposon insertions in a greater number of genes. For example, in the  
case of bacterial libraries, Tn5 and Tn10 libraries for example, could be combined.

### Generation of consensus probes

A consensus probe is generated from polynucleotide sequences that flank the transposons. The consensus probe may comprise polynucleotide sequences from one or both sides of any transposon. This will generally depend on the type of method used to generate the consensus probe. For example, inverse PCR generally leads to the isolation of polynucleotide sequences from both sides of a transposon, whereas vectorette PCR typically leads to the isolation of polynucleotide sequence from one side of a transposon.

Generally flanking sequence will be isolated from at least 80%, preferably at least 90%, more preferably at least 95% and most preferably at least 99% of the mutants in a particular library, panel or pool, of mutants.

Any method known to those in the art may be used to isolate polynucleotide sequences flanking transposons and thus to generate consensus probes.

A preferred method involves the isolation of two consensus probes: a left-arm consensus probe (comprising sequences flanking the left hand sides of the transposons) and a right-arm consensus probe (comprising sequences flanking the right hand sides of the transposons). Each consensus probe is generally isolated by restriction endonuclease digestion, ligation of a linker such as a vectorette unit and PCR (Figure 1).

Genomic DNA is isolated from a library of transposon mutants and digested with a first restriction endonuclease that cuts near the end of the transposon. Typically, suitable endonucleases have hexanucleotide recognition sequences. The exact restriction endonuclease used will depend on the sequence of the transposon which was used to generate the transposon-tagged library. These enzymes are referred to as the Transposon-specific (T-specific) endonucleases. In the case of *TnphoA*, the T-specific endonucleases are *DraI*, which cuts close to the left hand end of the transposon, and *HpaI*, which cuts close to the right hand end of the transposon (Figure 1). Generally, an aliquot of the library is digested with the left hand T-specific endonuclease and a further aliquot is separately digested with the right hand T-specific endonuclease.

The resulting fragment pools are separately digested with a further restriction

endonuclease, which will typically be different from the T-specific endonuclease. The second endonuclease, the Gene-specific (G-specific) endonuclease, is intended to cut somewhere in the genomic sequence that has been disrupted by the transposon. Generally, the G-specific endonuclease will have a four base pair recognition sequence and suitable examples are given in Table 1 below:

Table 1. Examples of 4bp recognition type II restriction endonucleases suitable for use in TMDH

Enzyme	Recognition Site	Enzyme	Recognition Site
<i>AccI</i>	C'CGC GGC <sub>1</sub> G	<i>MseI</i>	T'TAA AAT <sub>1</sub> T
<i>AluI</i>	AG'CT TC <sub>1</sub> GA	<i>MspI</i>	C'CGG GGC <sub>1</sub> C
<i>BfaI</i>	C'TAG GAT <sub>1</sub> C	<i>NlaIII</i>	'CATG GTAC <sub>1</sub>
<i>Bstul</i>	CG'CG GC <sub>1</sub> GC	<i>RsaI</i>	GT'AC CA <sub>1</sub> TG
<i>DpnI</i>	'GATC CTAG <sub>1</sub>	<i>Sau3a</i>	'GATC CTAG <sub>1</sub>
<i>HaeIII</i>	GG'CC CC <sub>1</sub> GG	<i>TaqI</i>	T'CGA AGC <sub>1</sub> T
<i>HinPI</i>	G'CGC CGC <sub>1</sub> G	<i>Tsp509</i>	'AATT TTAA <sub>1</sub>

The resulting fragments may then be size selected. Typically fragments with a size of from approximately 200 to 600 bp are isolated, for example from a gel, and purified. The smaller the fragments isolated, the smaller the chance of the consensus probes including sequences from genes which lie next to genes which have been interrupted by transposons. Linkers, preferably vectorette units, are then ligated with the left- and right-arm fragment pools. The resulting fragments may be re-purified for example through a gel or by using spun-column chromatography.

PCR is then carried out using the left- and right-arm pools of fragments as templates and a primer pair comprising an oligonucleotide specific for a transposon sequence and a second oligonucleotide specific for a linker (eg. a vectorette) sequence (Figure 1g). The use of transposon- and vectorette-specific PCR primers results in the specific amplification of sequences that are adjacent to the sites of transposon insertion.

---

This technique results in the isolation of sequences flanking both sides of the transposons. These pools of flanking fragments, the left- and right-arm consensus probes, may be used in hybridisation experiments to determine the essential genes.

Alternative methods for generating a consensus probe include, for example, splinkerette-PCR, targetted gene walking PCR, restriction site PCR, capture PCR, panhandle PCR, boomerang DNA amplification (for a review of these techniques see Hui *et al.*, Cell Mol. Life Sci. 54 (1998) 1403-1411). The last technique has the disadvantage of isolating flanking sequences from both sides of a transposon simultaneously. Thus, only one consensus probe is generated using inverse PCR and that way of carrying out TMDH is not as sensitive as methods which allow the generation of left- and right-arm consensus probes

The majority of the techniques described above for the generation of a consensus probe require digestion of genomic DNA isolated from the library of transposon mutants with a G-specific restriction endonuclease (for example, *HaeIII* in Figure 1). It is possible that the particular G-specific endonuclease used in an experiment will not cut within the gene in which the transposon is inserted, or cuts at a large distance, for example more than 2kb, away from the insertion site. Therefore sequences from these genes will not form part of the consensus probe. Thus the generation of consensus probes may be carried out several times, each time using different G-specific restriction endonucleases. The greater the number of enzymes used to make consensus probes, the greater the likelihood of sequences from non-essential genes being represented in the consensus probes. A similar result may be achieved by combining two or more of the techniques for generating consensus probes.

Hybridization of consensus probes to gridded arrays

The sequences which comprise the consensus probes may be labelled for use as probes in hybridization experiments. Suitable labels include radioisotopes such as  $^{32}\text{P}$ ,  $^{33}\text{P}$  or  $^{35}\text{S}$ , enzyme labels or other labels such as biotin or digoxigenin or fluorescent labels. These labels may be detected using methods well known to those skilled in the art.

---

Generally the consensus probe is hybridized with polynucleotides isolated from the organism being studied. The polynucleotides used will typically be in the form of a library and generally be from a wild type organism. Genomic or cDNA libraries, for example, could be used. Polynucleotides in the library to which the consensus probes do not hybridize may comprise all or part of an essential gene.

Ideally, a library used in a hybridization experiment will be in the form of a gridded array. Gridded arrays typically comprise a different clone at every location on the array and preferably the array represents the whole of an organism's genome (if the array is a genomic DNA array) ie. it may represent the whole of a bacterial genome, for example. Alternatively, the array could be an expression array, in which case it would preferably comprise all messages from a particular organism. Particularly preferred libraries are those where each location of the gridded array represents a single open reading frame of the organism, wherein all the open reading frames from the organism are represented. In that way all protein coding polynucleotide sequences are represented. The advantage of using gridded arrays is that a whole genome may be analyzed in one experiment, very quickly and the clones to which the consensus probe does not hybridize are immediately available in a purified form. Additionally, in the case of an organism whose entire genome has been sequenced, for example *E. coli* or *S. cerevisiae*, the order of all open reading frames in the genome is known. Therefore, the order of all the open reading frames represented on a gridded array is known. This may be useful in interpreting hybridisation results, as is described below.

Hybridization experiments are typically carried out using two copies of the gridded array. In such experiments, the first array may be hybridized with a left-arm consensus probe, while the second array is hybridized with the corresponding



right-arm consensus probe.

A location which on both the left- and right-arm arrays shows no hybridisation is likely to correspond to an essential gene. Figure 2, however, shows that in some cases small regions of essential gene sequence may be isolated in a  
5 consensus probe in the event of a transposon inserting close to the end of a non-

~~essential gene which lies adjacent to an essential gene. Thus essential genes may be~~  
capable of generating a small hybridisation signal on an array. An essential gene may give a hybridisation signal at a particular location only on one of the right and left arm arrays. Therefore not all clones on an array which give a positive signal  
10 should be classed as non-essential.

However, the amount of hybridisation seen for an essential gene will typically be much lower than that seen for an adjacent non-essential gene. This can be seen from Figure 2 which shows two important aspects of TMDH. Firstly, it is desirable that as many different insertions are obtained for as many genes as possible in the  
15 genome under study. Secondly, the use of an array from an organism whose entire genome has been sequenced and therefore where the order of genes in the genome is known may be crucial in interpreting the results of hybridisations.

#### Identification of conditional essential genes

20 The method may also be used for the identification of conditional essential genes. Conditional essential genes are those which are not absolutely essential for bacterial survival, but are essential for survival in particular environments eg. survival in a host (in the case of a pathogenic bacterium) or survival at elevated temperatures. Such environments are known as conditional restraints.

25 In order to isolate conditional essential genes, a library of transposon mutants is generated under control conditions (eg. growth at 37°C in complete media). The library of mutants is then subjected to some conditional restraint. For example, the library of mutants can be inoculated in a suitable host, if it is a pathogen. Alternatively, the library of mutants can be grown at an elevated temperature. After  
30 the library of mutants has been subjected to the conditional restraint it can be recovered.

The library of mutants that have been exposed to the conditional restraint will lack mutants which carry transposons in those genes essential for growth under the conditional environment.

5 The control and conditional restraint libraries can be subjected to TMDH as described above. Optionally, right- and left-arm consensus probes from the control library are pooled and right- and left-arm consensus probes from the conditional restraint library are pooled. The two resulting pools may then be hybridised separately to polynucleotide libraries, preferably in the form of gridded arrays. Alternatively, if the pooling step is not carried out, four separate hybridisations will  
10 be necessary: control left-arm consensus probe; control right-arm consensus probe; conditional restraint left-arm consensus probe; and conditional restraint right-arm consensus probe.

Comparison of the results given with the control and the conditional restraint libraries will allow the identification of genes which permit survival in the  
15 conditional restraint. Genes identified as essential for survival in the conditional restraint library, but not identified as essential for survival under control conditions should represent genes that are essential for survival under the conditional restraint.

In the case of the analysis of conditional mutations in a pathogen, a library of *Salmonella typhimurium* transposon mutants, for example, can be used to infect a  
20 mouse. Following infection, bacteria target to livers and spleens and the course of infection can be conveniently followed by performing viable bacterial counts on those organs. The bacteria recovered from the livers and spleens can be grown on suitable plates. In the case of the conditional restraint at elevated temperature, a transposon-tagged library can be grown at 42°C.

25 Other conditional restraints include growth of antibiotic resistant bacteria in the presence of antibiotics. This may reveal genes which are essential for antibiotic resistance. Such genes would be targets for drugs with the ability to lower bacterial resistance to particular antibiotics. Organisms could be grown in the presence of carcinogens, UV or other agents that cause oxidative stress and thus genes that confer  
30 resistance to growth under those conditions may be identified.

### Verification of the phenotype

Potential essential gene sequences and conditional essential gene sequences identified by the TMDH strategy may be verified using a method based on allelic exchange. This technique is particularly suitable for analysis of bacterial genes.

- 5 PCR primers can be used to generate left- and right-arm sequences corresponding to the target gene sequence and ligated with a kanamycin-resistance encoding gene cassette. The resulting cassette can be introduced into a suicide vector, for example a plasmid-based vector, which is unable to replicate in a host bacterium.

- 10 In the case of a candidate essential gene, the resulting construct can be introduced into the bacterial strain from which the candidate gene originates. If the target gene is essential, it should be impossible to isolate allelic-exchange mutants that have a disrupted version of the target gene. In the case of a candidate conditional essential gene, the essential gene can be introduced into the bacterial strain from which the candidate gene originates. Allelic-exchange mutants can be  
15 isolated and subjected to growth under the conditional restraint. If the candidate gene is a conditional essential gene, it should not be possible for the allelic-exchange mutants to survive under the conditional restraint.

Similar experiments may be performed for other organisms

### 20 Bioinformatics

- The use of bioinformatics may allow the rapid isolation of further essential and conditional essential genes. A gene identified in TMDH may be used to search databases containing sequence information from other species in order to identify orthologous genes from those species. Genes so identified can be tested for being  
25 essential or conditionally essential using the genetic techniques described above. For example, an *E. coli* gene is identified as essential using a method as described above. This may allow the identification of a putative orthologue from *Salmonella*. That *Salmonella* gene may be tested by allelic exchange and the construction of conditional mutants in *Salmonella* as described above. Further orthologues may be  
30 identified in more distantly related organisms, for example from *Plasmodium* species.

Suitable bioinformatics programs are well known to those skilled in the art. For example, the Basic Local Alignment Search Tool (BLAST) program (Altschul *et al.*, 1990, J. Mol. Biol. 215, 403-410. and Altschul *et al.*, 1997, Nucl. Acids Res. 25, 3389-3402.) may be used. Suitable databases for searching are for example, EMBL, GENBANK, TIGR, EBI, SWISS-PROT and trEMBL.

---

#### Organisms useful in the invention

Organisms that may be used in the invention are those for which it is possible to carry out transposon mutagenesis and thus, those that can give rise to a library of transposon mutants. Clearly, if the genome is bigger, more mutants will have to be produced in order to give a better chance of achieving saturation mutagenesis.

Suitable organisms include prokaryotic and eukaryotic organisms. Suitable prokaryotes include bacteria. Preferred bacteria are those which are animal or human or plant pathogens.

The bacteria used may be Gram-negative or Gram-positive. The bacteria may be for example, from the genera *Escherichia*, *Salmonella*, *Vibrio*, *Haemophilus*, *Neisseria*, *Yersinia*, *Bordetella*, *Brucella*, *Shigella*, *Klebsiella*, *Enterobacter*, *Serratia*, *Proteus*, *Vibrio*, *Aeromonas*, *Pseudomonas*, *Acinetobacter*, *Moraxella*, *Flavobacterium*, *Actinobacillus*, *Staphylococcus*, *Streptococcus*, *Mycobacterium*, *Listeria*, *Clostridium*, *Pasteurella*, *Helicobacter*, *Campylobacter*, *Lawsonia*, *Mycoplasma*, *Bacillus*, *Agrobacterium*, *Rhizobium*, *Erwinia* or *Xanthomonas*.

Examples of some of the above mentioned genera are *Escherichia coli* - a cause of diarrhoea in humans; *Salmonella typhimurium* - the cause of salmonellosis in several animal species; *Salmonella typhi* - the cause of human typhoid fever; *Salmonella enteritidis* - a cause of food poisoning in humans; *Salmonella choleraesuis* - a cause of salmonellosis in pigs; *Salmonella dublin* - a cause of both a systemic and diarrhoeal disease in cattle, especially of new-born calves; *Haemophilus influenzae* - a cause of meningitis; *Neisseria gonorrhoeae* - a cause of gonorrhoea; *Yersinia enterocolitica* - the cause of a spectrum of diseases in humans ranging from gastroenteritis to fatal septicemic disease; *Bordetella pertussis* - the cause of whooping cough; *Brucella abortus* - a cause of abortion and infertility in

cattle and a condition known as undulant fever in humans; *Vibrio cholerae* - a cause of cholera; *Clostridium tetani* - a cause of tetanus; *Bacillus anthracis* - a cause of anthrax.

5        Suitable eukaryotes include fungi, plants and animals. Preferred eukaryotes include animal or human parasites and plant pests.

---

10        ~~Suitable fungi include the animal pathogens including *Candida albicans* - a cause of thrush, *Trichophyton* spp. - a cause of ringworm in children, athlete's foot in adults. Other suitable fungi include the plant pathogens *Phytophthora infestans*, *Plasmopara viticola*, *Peronospora* spp., *Saprolegnia* spp., *Erysiphe* spp.,~~  
*Ceratocystis ulmi*, *Monilinia fructigena*, *Venturia inequalis*, *Claviceps purpurea*, *Diplocarpon rosae*, *Puccinia graminis*, *Ustilago avenae*.

15        Suitable animal parasites include Plasmodium spp., Trypanasoma spp., Giardia spp., Trichomonas spp. and Schistosoma spp. Other animal parasites include the various platyhelminth, nematode and annelid parasites.

15        Suitable plant pests include insects, nematodes and molluscs such as slugs and snails.

Suitable plants include monocotyledons and dicotyledons.

20        Preferred organisms are those for which the entire genome has been sequenced and therefore for which it may be possible to construct gridded arrays covering the entire genome or all of the open reading frames.

#### Screens for inhibitors of essential and conditional essential genes

25        Essential and conditional essential genes of bacteria and the polypeptides which they encode may represent targets for antibacterial substances. Similarly essential and conditional essential genes of fungi and eukaryotic parasites, pests and plants and the proteins which they encode may represent targets for fungicides, antiparasitics, pesticides and herbicides respectively. Fungicides may have both animal and plant applications.

30        Furthermore, if a particular gene is essential or conditionally essential for a number of different bacteria, fungi, parasites, pests or plants, that gene and the polypeptide it encodes may represent a target for substances with a broad-spectrum

of activity.

An essential or conditional essential gene identified by a method as described above and the polypeptide which it encodes may be used in a method for identifying an inhibitor of transcription and/or translation of the gene and/or activity of the

5 polypeptide encoded by the gene. Such a substance may be referred to as an

~~inhibitor of an essential or conditional essential gene. Thus, an inhibitor of an~~

essential or conditional essential gene is a substance which inhibits expression and/or translation of that essential gene and/or activity of the polypeptide encoded by that essential or conditional essential gene.

10 Any suitable assay may be carried out to determine whether a test substance is an inhibitor of an essential or conditional essential gene. For example, the promoter of an essential or conditional essential gene may be linked to a coding sequence for a reporter polypeptide. Such a construct may be contacted with a test substance under conditions in which, in the absence of the test substance expression  
15 of the reporter polypeptide would occur. This would allow the effect of the test substance on expression of the essential or conditional essential gene to be determined.

Substances which inhibit translation of an essential or conditional essential gene may be isolated, for example, by contacting the mRNA of the essential or  
20 conditional essential gene with a test substance under conditions that would permit translation of the mRNA in the absence of the test substance. This would allow the effect of the test substance on translation of the essential or conditional essential gene to be determined.

Substances which inhibit activity of a polypeptide encoded by the essential  
25 gene may be isolated, for example, by contacting the polypeptide with a substrate for the polypeptide and a test substance under conditions that would permit activity of the polypeptide in the absence of the test substance. This would allow the effect of the test substance on activity of the polypeptide encoded by the essential or conditional essential gene to be determined.

30 Suitable control experiments can be carried out. For example, a putative inhibitor should be tested for its activity against other promoters, mRNAs or

polypeptides to discount the possibility that it is a general inhibitor of gene transcription, translation or polypeptide activity.

#### Test Substances

5            Suitable test substances for inhibitors of essential or conditional essential  
~~genes include combinatorial libraries, defined chemical entities, peptides and peptide~~  
mimetics, oligonucleotides and natural product libraries. The test substances may be  
used in an initial screen of, for example, ten substances per reaction, and the  
substances of batches which show inhibition tested individually. Furthermore,  
10        antibody products (for example, monoclonal and polyclonal antibodies, single chain  
antibodies, chimaeric antibodies and CDR-grafted antibodies) may be used.

#### Inhibitors of essential genes

15            An inhibitor of an essential or conditional essential gene is one which inhibits  
expression and/or translation of that essential gene and/or activity of the polypeptide  
encoded by that essential or conditional gene. Preferred substances are those which  
inhibit essential gene expression and/or translation and/or activity by at least 10%, at  
least 20%, at least 30%, at least 40%, at least 50%, at least 60%, at least 70%, at least  
80%, at least 90%, at least 95% or at least 99% at a concentration of the inhibitor of  
20        1  $\mu\text{gml}^{-1}$ , 10  $\mu\text{gml}^{-1}$ , 100  $\mu\text{gml}^{-1}$ , 500  $\mu\text{gml}^{-1}$ , 1  $\text{mgml}^{-1}$ , 10  $\text{mgml}^{-1}$ , 100  $\text{mg ml}^{-1}$ . The  
percentage inhibition represents the percentage decrease in expression and/or  
translation and/or activity in a comparison of assays in the presence and absence of  
the test substance. Any combination of the above mentioned degrees of percentage  
inhibition and concentration of inhibitor may be used to define an inhibitor of the  
25        invention, with greater inhibition at lower concentrations being preferred.

Test substances which show activity in assays such as those described above  
can be tested in *in vivo* systems, such as an animal model of infection for  
antibacterial activity or a plant model for herbicidal activity. Thus, candidate  
inhibitors could be tested for their ability to attenuate bacterial infections in mice in  
30        the case of an antibacterial or for their ability to inhibit growth of plants in the case of  
a herbicide.

Therapeutic use

Inhibitors of bacterial, fungal or eukaryotic parasite essential or conditional essential genes may be used in a method of treatment of the human or animal body by therapy. In particular such substances may be used in a method of treatment of a  
5 ~~bacterial, fungal or eukaryotic parasite infection. Such substances may also be used~~  
for the manufacture of a medicament for use in the treatment of a bacterial, fungal or eukaryotic parasite infections. The condition of a patient suffering from such an infection can be improved by administration of an inhibitor. A therapeutically  
10 effective amount of an inhibitor may be given to a human patient in need thereof.

Inhibitors of bacterial, fungal or eukaryotic parasite essential or conditional essential genes may be administered in a variety of dosage forms. Thus, they can be administered orally, for example as tablets, troches, lozenges, aqueous or oily suspensions, dispersible powders or granules. The inhibitors may also be  
15 administered parenterally, either subcutaneously, intravenously, intramuscularly, intrasternally, transdermally or by infusion techniques. The inhibitors may also be administered as suppositories. A physician will be able to determine the required route of administration for each particular patient.

The formulation of an inhibitor for use in preventing or treating a bacterial or  
20 fungal infection will depend upon factors such as the nature of the exact inhibitor, whether a pharmaceutical or veterinary use is intended, etc. An inhibitor may be formulated for simultaneous, separate or sequential use.

An inhibitor is typically formulated for administration in the present invention with a pharmaceutically acceptable carrier or diluent. The pharmaceutical  
25 carrier or diluent may be, for example, an isotonic solution. For example, solid oral forms may contain, together with the active compound, diluents, e.g. lactose, dextrose, saccharose, cellulose, corn starch or potato starch; lubricants, e.g. silica, talc, stearic acid, magnesium or calcium stearate, and/or polyethylene glycols; binding agents; e.g. starches, gum arabic, gelatin, methylcellulose,  
30 carboxymethylcellulose or polyvinyl pyrrolidone; disaggregating agents, e.g. starch, alginic acid, alginates or sodium starch glycolate; effervescing mixtures; dyestuffs;



sweeteners; wetting agents, such as lecithin, polysorbates, laurylsulphates; and, in general, non-toxic and pharmacologically inactive substances used in pharmaceutical formulations. Such pharmaceutical preparations may be manufactured in known manner, for example, by means of mixing, granulating, tableting, sugar-coating, or film-coating processes.

---

Liquid dispersions for oral administration may be syrups, emulsions or suspensions. The syrups may contain as carriers, for example, saccharose or saccharose with glycerine and/or mannitol and/or sorbitol.

Suspensions and emulsions may contain as carrier, for example a natural gum, agar, sodium alginate, pectin, methylcellulose, carboxymethylcellulose, or polyvinyl alcohol. The suspensions or solutions for intramuscular injections may contain, together with the active compound, a pharmaceutically acceptable carrier, e.g. sterile water, olive oil, ethyl oleate, glycols, e.g. propylene glycol, and if desired, a suitable amount of lidocaine hydrochloride.

Solutions for intravenous administration or infusion may contain as carrier, for example, sterile water or preferably they may be in the form of sterile, aqueous, isotonic saline solutions.

A therapeutically effective amount of an inhibitor is administered to a patient. The dose of an inhibitor may be determined according to various parameters, especially according to the substance used; the age, weight and condition of the patient to be treated; the route of administration; and the required regimen. Again, a physician will be able to determine the required route of administration and dosage for any particular patient. A typical daily dose is from about 0.1 to 50 mg per kg of body weight, according to the activity of the specific inhibitor, the age, weight and conditions of the subject to be treated, the type and severity of the degeneration and the frequency and route of administration. Preferably, daily dosage levels are from 5 mg to 2 g.

#### Live Attenuated Vaccines

The principle behind vaccination is to induce an immune response in the host thus providing protection against subsequent challenge with a pathogen. This may be

achieved by inoculation with a live attenuated strain of the pathogen, i.e. a strain having reduced virulence such that it does not cause the disease caused by the virulent pathogen. Bacteria which carry mutations in conditional essential genes required for survival in a host isolated according to the methods described above may be good candidates for use in live attenuated vaccines.

5        The mutations introduced into the bacterial vaccine generally knock-out the  
function of the gene completely. This may be achieved either by abolishing synthesis of any polypeptide at all from the gene or by making a mutation that results in synthesis of non-functional polypeptide. In order to abolish synthesis of polypeptide,  
10       either the entire gene or its 5'-end may be deleted. A deletion or insertion within the coding sequence of a gene may be used to create a gene that synthesises only non-functional polypeptide (e.g. polypeptide that contains only the N-terminal sequence of the wild-type protein).

      The bacterium may have mutations in one or more, for example two, three or  
15       four conditional essential genes. The mutations are non-reverting mutations. These are mutations that show essentially no reversion back to the wild-type when the bacterium is used as a vaccine. Such mutations include insertions and deletions. Insertions and deletions are preferably large, typically at least 10 nucleotides in length, for example from 10 to 600 nucleotides. Preferably, the whole coding  
20       sequence is deleted.

      The bacterium used in the vaccine preferably contains only defined mutations, i.e. mutations which are characterised. It is clearly undesirable to use a bacterium which has uncharacterised mutations in its genome as a vaccine because there would be a risk that the uncharacterised mutations may confer properties on the  
25       bacterium that cause undesirable side-effects.

      The attenuating mutations may be introduced by methods well known to those skilled in the art. Appropriate methods include cloning the DNA sequence of the wild-type gene into a vector, e.g. a plasmid, and inserting a selectable marker into the cloned DNA sequence or deleting a part of the DNA sequence, resulting in its  
30       inactivation. A deletion may be introduced by, for example, cutting the DNA sequence using restriction enzymes that cut at two points in or just outside the coding

sequence and ligating together the two ends in the remaining sequence with an antibiotic resistance determinant. A plasmid carrying the inactivated DNA sequence can be transformed into the bacterium by known techniques such as electroporation or conjugation for example. It is then possible by suitable selection to identify a mutant wherein the inactivated DNA sequence has recombined into the chromosome of the bacterium and the wild-type DNA sequence has been rendered non-functional by homologous recombination.

The attenuated bacterium of the invention may be genetically engineered to express an antigen that is not expressed by the native bacterium (a "heterologous antigen"), so that the attenuated bacterium acts as a carrier of the heterologous antigen. The antigen may be from another organism, so that the vaccine provides protection against the other organism. A multivalent vaccine may be produced which not only provides immunity against the virulent parent of the attenuated bacterium but also provides immunity against the other organism. Furthermore, the attenuated bacterium may be engineered to express more than one heterologous antigen, in which case the heterologous antigens may be from the same or different organisms.

The heterologous antigen may be a complete protein or a part of a protein containing an epitope. The antigen may be from a virus, prokaryote or a eukaryote, for example another bacterium, a yeast, a fungus or a eukaryotic parasite. The antigen may be from an extracellular or intracellular protein. More especially, the antigenic sequence may be from *E.coli*, tetanus, hepatitis A, B or C virus, human rhinovirus such as type 2 or type 14, herpes simplex virus, poliovirus type 2 or 3, foot-and-mouth disease virus, influenza virus, coxsackie virus or *Chlamydia trachomatis*. Useful antigens include non-toxic components of *E.coli* heat labile toxin, *E.coli* K88 antigens, ETEC colonization factor antigens, P.69 protein from *B.pertussis* and tetanus toxin fragment C.

The DNA encoding the heterologous antigen is expressed from a promoter that is active *in vivo*. Two promoters that have been shown to work well in *Salmonella* are the *nirB* promoter and the *htrA* promoter. For expression of the ETEC colonization factor antigens, the wild-type promoters could be used.

A DNA construct comprising the promoter operably linked to DNA encoding

the heterologous antigen may be made and transformed into the attenuated bacterium using conventional techniques. Transformants containing the DNA construct may be selected, for example by screening for a selectable marker on the construct. Bacteria containing the construct may be grown *in vitro* before being formulated for administration to the host for vaccination purposes.

---

The vaccine may be formulated using known techniques for formulating

attenuated bacterial vaccines. The vaccine is advantageously presented for oral administration, for example in a lyophilised encapsulated form. Such capsules may be provided with an enteric coating comprising, for example, Eudragate "S" (Trade Mark), Eudragate "L" (Trade Mark), cellulose acetate, cellulose phthalate or hydroxypropylmethyl cellulose. These capsules may be used as such, or alternatively, the lyophilised material may be reconstituted prior to administration, e.g. as a suspension. Reconstitution is advantageously effected in a buffer at a suitable pH to ensure the viability of the bacteria. In order to protect the attenuated bacteria and the vaccine from gastric acidity, a sodium bicarbonate preparation is advantageously administered before each administration of the vaccine. Alternatively, the vaccine may be prepared for parenteral administration, intranasal administration or intramuscular administration.

The vaccine may be used in the vaccination of a mammalian host, particularly a human host but also an animal host. An infection caused by a microorganism, especially a pathogen, may therefore be prevented by administering an effective dose of a vaccine prepared according to the invention. The dosage employed will ultimately be at the discretion of the physician, but will be dependent on various factors including the size and weight of the host and the type of vaccine formulated. However, a dosage comprising the oral administration of from  $10^7$  to  $10^{11}$  bacteria per dose may be convenient for a 70 kg adult human host.

Agricultural use

Inhibitors of bacterial, fungal and pest essential or conditional essential genes may be administered to plants in order to prevent or treat bacterial, fungal or pest infections; the term pest includes any animal which attacks a plant. Thus inhibitors

of the invention may be useful as pesticides. Inhibitors of plant essential or conditional essential genes may be administered to plants in order to reduce or stop plant growth, that is to act as a herbicide.

5 The inhibitors of the present invention are normally applied in the form of compositions together with one or more agriculturally acceptable carriers or diluents and can be applied to the crop area or plant to be treated, simultaneously or in succession with further compounds.

10 The inhibitors of the invention can be selective herbicides, bacteriocides, fungicides or pesticides or mixtures of several of these preparations, if desired together with further carriers, surfactants or application-promoting adjuvants customarily employed in the art of formulation. Suitable carriers and diluents correspond to substances ordinarily employed in formulation technology, e.g. natural or regenerated mineral substances, solvents, dispersants, wetting agents, tackifiers, binders or fertilizers.

15 A preferred method of applying active ingredients of the present invention or an agrochemical composition which contains at least one of the active ingredients is leaf application. The number of applications and the rate of application depend on the intensity of infestation by the pathogen. However, the active ingredients can also penetrate the plant through the roots via the soil (systemic action) by impregnating the locus of the plant with a liquid composition, or by applying the compounds in solid form to the soil, e.g. in granular form (soil application). The active ingredients may also be applied to seeds (coating) by impregnating the seeds either with a liquid formulation containing active ingredients, or coating them with a solid formulation. In special cases, further types of application are also possible, for example, selective treatment of the plant stems or buds.

25 The active ingredients are used in unmodified form or, preferably, together with the adjuvants conventionally employed in the art of formulation, and are therefore formulated in known manner to emulsifiable concentrates, coatable pastes, directly sprayable or dilutable solutions, dilute emulsions, wettable powders, soluble powders, dusts, granulates, and also encapsulations, for example, in polymer substances. Like the nature of the compositions, the methods of application, such as

spraying, atomizing, dusting, scattering or pouring, are chosen in accordance with the intended objectives and the prevailing circumstances. Advantageous rates of application are normally from 50g to 5kg of active ingredient (a.i.) per hectare ("ha", approximately 2.471 acres), preferably from 100g to 2kg a.i./ha, most preferably from 200g to 500g a.i./ha.

---

The formulations, compositions or preparations containing the active

ingredients and, where appropriate, a solid or liquid adjuvant, are prepared in known manner, for example by homogeneously mixing and/or grinding active ingredients with extenders, for example solvents, solid carriers and, where appropriate, surface-active compounds (surfactants).

Suitable solvents include aromatic hydrocarbons, preferably the fractions having 8 to 12 carbon atoms, for example, xylene mixtures or substituted naphthalenes, phthalates such as dibutyl phthalate or dioctyl phthalate, aliphatic hydrocarbons such as cyclohexane or paraffins, alcohols and glycols and their ethers and esters, such as ethanol, ethylene glycol, monomethyl or monoethyl ether, ketones such as cyclohexanone, strongly polar solvents such as N-methyl-2-pyrrolidone, dimethyl sulfoxide or dimethyl formamide, as well as epoxidized vegetable oils such as epoxidized coconut oil or soybean oil; or water.

The solid carriers used e.g. for dusts and dispersible powders, are normally natural mineral fillers such as calcite, talcum, kaolin, montmorillonite or attapulgite. In order to improve the physical properties it is also possible to add highly dispersed silicic acid or highly dispersed absorbent polymers. Suitable granulated adsorptive carriers are porous types, for example pumice, broken brick, sepiolite or bentonite; and suitable nonsorbent carriers are materials such as calcite or sand. In addition, a great number of pregranulated materials of inorganic or organic nature can be used, e.g. especially dolomite or pulverized plant residues.

Depending on the nature of the active ingredient to be used in the formulation, suitable surface-active compounds are nonionic, cationic and/or anionic surfactants having good emulsifying, dispersing and wetting properties. The term "surfactants" will also be understood as comprising mixtures of surfactants.

Suitable anionic surfactants can be both water-soluble soaps and water-

soluble synthetic surface-active compounds.

Suitable soaps are the alkali metal salts, alkaline earth metal salts or unsubstituted or substituted ammonium salts of higher fatty acids (chains of 10 to 22 carbon atoms), for example the sodium or potassium salts of oleic or stearic acid, or of natural fatty acid mixtures which can be obtained for example from coconut oil or tallow oil. The fatty acid methyltaurin salts may also be used.

---

More frequently, however, so-called synthetic surfactants are used, especially fatty sulfonates, fatty sulfates, sulfonated benzimidazole derivatives or alkylarylsulfonates.

The fatty sulfonates or sulfates are usually in the form of alkali metal salts, alkaline earth metal salts or unsubstituted or substituted ammoniums salts and have a 8 to 22 carbon alkyl radical which also includes the alkyl moiety of alkyl radicals, for example, the sodium or calcium salt of lignonsulfonic acid, of dodecylsulfate or of a mixture of fatty alcohol sulfates obtained from natural fatty acids. These compounds also comprise the salts of sulfuric acid esters and sulfonic acids of fatty alcohol/ethylene oxide adducts. The sulfonated benzimidazole derivatives preferably contain 2 sulfonic acid groups and one fatty acid radical containing 8 to 22 carbon atoms. Examples of alkylarylsulfonates are the sodium, calcium or triethanolamine salts of dodecylbenzenesulfonic acid, dibutyl-naphthalenesulfonic acid, or of a naphthalenesulfonic acid/formaldehyde condensation product. Also suitable are corresponding phosphates, e.g. salts of the phosphoric acid ester of an adduct of p-nonylphenol with 4 to 14 moles of ethylene oxide.

Non-ionic surfactants are preferably polyglycol ether derivatives of aliphatic or cycloaliphatic alcohols, or saturated or unsaturated fatty acids and alkylphenols, said derivatives containing 3 to 30 glycol ether groups and 8 to 20 carbon atoms in the (aliphatic) hydrocarbon moiety and 6 to 18 carbon atoms in the alkyl moiety of the alkylphenols.

Further suitable non-ionic surfactants are the water-soluble adducts of polyethylene oxide with polypropylene glycol, ethylenediamine propylene glycol and alkylpolypropylene glycol containing 1 to 10 carbon atoms in the alkyl chain, which adducts contain 20 to 250 ethylene glycol ether groups and 10 to 100

propylene glycol ether groups. These compounds usually contain 1 to 5 ethylene glycol units per propylene glycol unit.

Representative examples of non-ionic surfactants are nonylphenolpolyethoxyethanols, castor oil polyglycol ethers,

5 polypropylene/polyethylene oxide adducts, tributylphenoxypolyethoxyethanol, polyethylene glycol and octylphenoxypolyethoxyethanol. Fatty acid esters of

polyoxyethylene sorbitan and polyoxyethylene sorbitan trioleate are also suitable non-ionic surfactants.

Cationic surfactants are preferably quaternary ammonium salts which have, as  
10 N-substituent, at least one C<sub>8</sub>-C<sub>22</sub> alkyl radical and, as further substituents, lower unsubstituted or halogenated alkyl, benzyl or lower hydroxyalkyl radicals. The salts are preferably in the form of halides, methylsulfates or ethylsulfates, e.g. stearyltrimethylammonium chloride or benzyldi(2-chloroethyl)ethylammonium bromide.

15 The surfactants customarily employed in the art of formulation are described, for example, in "McCutcheon's Detergents and Emulsifiers Annual", MC Publishing Corp. Ringwood, New Jersey, 1979, and Sisely and Wood, "Encyclopaedia of Surface Active Agents," Chemical Publishing Co., Inc. New York, 1980.

The agrochemical compositions usually contain from about 0.1 to about 99%  
20 preferably about 0.1 to about 95%, and most preferably from about 3 to about 90% of the active ingredient, from about 1 to about 99.9%, preferably from about 1 to 99%, and most preferably from about 5 to about 95% of a solid or liquid adjuvant, and from about 0 to about 25%, preferably about 0.1 to about 25%, and most preferably from about 0.1 to about 20% of a surfactant.

25 Whereas commercial products are preferably formulated as concentrates, the end user will normally employ dilute formulations.

### **Example**

Unless indicated otherwise, the methods used are standard biochemical  
30 techniques. Examples of suitable general methodology textbooks include Sambrook *et al.*, Molecular Cloning, a Laboratory Manual (1989) and Ausubel *et al.*, Current



Protocols in Molecular Biology (1995), John Wiley & Sons, Inc.

A flow diagram outlining the TMDH procedure is shown in Figure 1.

Following the generation of a transposon library, DNA is purified from

5 approximately 50 000 colonies (Figure 1a and 1b). In order to generate probes for  
~~the differential hybridization, gene sequences flanking the site of transposon insertion~~  
are recovered by a strategy involving double restriction endonuclease digestion  
(Figure 1c). Left- and right-arm fragments in the 200 to 600bp size range are  
purified by gel electrophoresis (Figure 1d and 1e) and vectorette units ligated onto the  
10 ends (Figure 1f).

In order to generate a specific probe population for subsequent hybridisation  
to the gene array filter, PCR is carried out with primer pairs specific for the  
transposon and the vectorette (Figure 1g). Figure 3 shows a gel analysis of the PCR  
amplification of left- and right-arms generated using this approach. The PCR step is  
15 designed to amplify only those sequences that have been disrupted by transposon  
insertion (Figure 3, tracks 2 and 4). The effectiveness of this step is seen from  
analysis of tracks 3 and 5, where DNA from an *E. coli* isolate not harbouring a  
transposon is subjected to PCR with the same primers and results in no detectable  
amplification. Following amplification, the two probe populations produced from  
20 the left- and right-arms are radioactively labelled (Figure 1h) and hybridized to an *E.*  
*coli* gridded array library (Figure 1i).

Figure 4a and 4b shows the result produced following hybridisation with the  
left- and right-arm probes. A positive hybridisation signal on the array corresponds  
to a gene that has been disrupted by transposon insertion and is consequently unlikely  
25 to be essential.

CLAIMS

1. A method for identifying an essential gene of an organism comprising:
  - (i) providing a library of transposon mutants of the said organism;
  - 5 (ii) isolating polynucleotide sequences from the library which flank  
~~inserted transposons;~~
  - (iii) hybridising the said polynucleotide sequences with a polynucleotide library from the said organism; and
  - (iv) identifying a polynucleotide in the said polynucleotide library to  
10 which the said polynucleotide sequences do not hybridise, thereby to determine an essential gene of the organism.
2. A method according to claim 1, wherein the said polynucleotide library is in the form of a gridded array.  
15
3. A method according to claim 1 or 2, wherein the organism is a bacterium, yeast, fungus, plant or animal.
4. A method according to any one of the preceding claims, wherein:  
20 in step (ii) polynucleotide sequences flanking one side of the transposons are isolated to give a pool of sequences and polynucleotide sequences flanking the other side of the transposons are isolated to give a separate second pool of sequences; and  
in step (iii) the first pool of sequences is hybridised with a first sample of the said polynucleotide library and the second pool of sequences is hybridised with a  
25 second sample of the said polynucleotide library.
5. A method according to claim 4, wherein in step (ii) each pool of sequences is isolated by a method comprising:
  - (a) digesting genomic DNA isolated from a library of transposon-tagged  
30 mutants with a restriction endonuclease that cuts within the transposon (T-specific endonuclease) and a second different

restriction endonuclease (G-specific endonuclease) which cuts within the disrupted sequence;

- (b) ligating the resulting DNA fragments with a linker;
- (c) carrying out PCR on the resulting DNA fragments with an oligonucleotide specific for a transposon sequence and an

5

~~oligonucleotide specific for a linker sequence.~~

---

6. A method according to claim 4 or 5, wherein the library of transposon mutants is a library of *TnphoA E. coli* mutants.

10

7. A method according to claim 6, wherein:

in the isolation of the first pool of sequences the restriction enzyme which cuts in the transposon is *DraI* and the second enzyme is a 4 base pair restriction endonuclease; and

15

in the isolation of the second pool of sequences the restriction enzyme which cuts in the transposon is *HpaI* and the second enzyme is a 4 base pair restriction endonuclease.

8. A method for identifying a conditional essential gene of an organism comprising:

20

- (i) providing a first sample of a library of transposon mutants of the said organism (input library);
- (ii) providing a second sample of the library and subjecting that sample to a conditional restraint;
- (iii) collecting the mutants that survive the conditional restraint in step (ii) to give a new library (output library);
- (iv) carrying out a method according to any one of the preceding claims on the input library from step (i) and on the output library from step (iii), thereby to determine a conditional essential gene of the organism.

25

30

9. Use of an essential gene identified by a method according to any one of

claims 1 to 7 or a conditional essential gene according to claim 8, or the polypeptide encoded by a said gene, in a method for identifying an inhibitor of transcription and/or translation of that gene and/or activity of a polypeptide encoded by that gene.

5        10.     A method for identifying:

~~(i)     an inhibitor of transcription and/or translation of an essential gene~~  
identified by a method according to any one of claims 1 to 7 or a conditional essential gene identified by a method according to claim 8; and/or

10            (ii)     an inhibitor of activity of a polypeptide encoded by a said gene, which method comprises determining whether a test substance can inhibit transcription and/or translation of a said gene and/or activity of a polypeptide encoded by a said gene.

15        11.     An inhibitor identified by a method according to claim 10.

12.     An inhibitor of transcription and/or translation of an essential or conditional essential gene and/or activity of a polypeptide encoded by that gene.

20        13.     An inhibitor according to claim 11 or 12, wherein the essential or conditional essential gene is a bacterial, fungal or eukaryotic parasite essential or conditional essential gene.

14.     An inhibitor according to claim 13 for use in a method of treatment of the  
25     human or animal body by therapy.

15.     An inhibitor according to claim 14 for use in a method of treatment of a bacterial, fungal or eukaryotic parasite infection.

30        16.     Use of an inhibitor according to claim 13 for the manufacture of a medicament for use in the treatment of a bacterial, fungal or eukaryotic parasite

infection.

17. A pharmaceutical composition comprising an inhibitor according to claim 13 and a pharmaceutically acceptable carrier or diluent.

5

---

18. ~~A method of treating a host suffering from a bacterial, fungal or eukaryotic~~  
parasite infection, which comprises administering to the host a therapeutically  
effective amount of an inhibitor according to claim 13.

10 19. An inhibitor according to claim 11 or 12, wherein the essential or conditional  
essential gene is a bacterial, fungal or pest essential or conditional essential gene.

20. Use of an inhibitor according to 19 as a plant bactericide, fungicide or  
pesticide.

15

21. An inhibitor according to claim 11 or 12, wherein essential or conditional  
essential gene is a plant conditional or essential gene.

22. Use of an inhibitor according to claim 21 as a herbicide.

20

23. A method according to claim 8, wherein the organism is a bacterium and the  
conditional restraint is growth of that bacterium in its host.

24. A bacterium attenuated by a non-reverting mutation in one or more genes  
25 identified by a method as defined in claim 23.

25. A vaccine comprising a bacterium according to claim 24 and a  
pharmaceutically acceptable carrier or diluent.

30 26. A bacterium according to claim 24 for use in a method of vaccinating a  
human or animal.

27. Use of a bacterium according to claim 24 for the manufacture of a medicament for vaccinating a human or animal.

28. A method of raising an immune response in a mammalian host, which  
5 comprises administering to the host a bacterium according to claim 24.

---

10

15

20

**ABSTRACT**

**Transposon Mediated Differential Hybridization**

5 A method for identifying an essential gene of an organism comprises:

- 
- (i) ~~providing a library of transposon mutants of the said organism;~~
  - (ii) isolating polynucleotide sequences from the library which flank  
inserted transposons;
  - (iii) hybridising the said polynucleotide sequences with a polynucleotide  
10 library from the said organism; and
  - (iv) identifying a polynucleotide in the said polynucleotide library to  
which the said polynucleotide sequences do not hybridise, thereby to  
determine an essential gene of the organism.

15

\_\_\_\_\_




# IMDH - A NOVEL STRATEGY FOR IDENTIFYING ESSENTIAL MICROBIAL GENES

- (A) Generate *E.coli* transposon library  
 Prepare chromosomal DNA from ~50,000 colonies  
 (C) Double restriction endonuclease digests of Left and Right arm DNA

Left arm

Right arm




- (D) Separate Left and Right arms prepared with T- and G-specific restriction endonucleases

- (E) Size select restriction fragments

- (F) Ligate vectorette to size-selected fragments

- (G) 'Left arm' PCR

- 'Right arm' PCR



- (H) Radiolabel PCR products

- Radiolabel PCR products

- (I) Hybridise to gene arrays



- (J) DATA ANALYSIS - IDENTIFY NON-HYBRIDISING GENES

Figure 1

\_\_\_\_\_

# Generation of Left and Right arm hybridisation probes: Interpretation of signal intensity




Figure 2

\_\_\_\_\_




Figure 3

.....

File Name:array4a.tif, 5/7/99 15:41:25, Range:1-83, Bitmap:Linear, Palette:Linear,Actual Size




Figure 4a

• • •  
•

---

•





File Name: array3a.tif, 5/7/99 15:02:51, Range: 1-53, Bitmap: Linear, Palette: Linear, Actual Size




Figure 4b

PCT / GB00 / 02879

JA Kemp + Co

26/7/00

---